APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antihemophilic Factor & von Willebrand Factor Complex

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antihemophilic Factor & von Willebrand Factor Complex Market Analysis and Forecast 2026-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchAntihemophilic Factor & von Willebrand Factor Complex Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Antihemophilic Factor & von Willebrand Factor Complex Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Antihemophilic Factor & von Willebrand Factor Complex Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antihemophilic Factor & von Willebrand Factor Complex Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Antihemophilic Factor & von Willebrand Factor Complex Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Antihemophilic Factor & von Willebrand Factor Complex market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Antihemophilic Factor & von Willebrand Factor Complex is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antihemophilic Factor & von Willebrand Factor Complex is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antihemophilic Factor & von Willebrand Factor Complex is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antihemophilic Factor & von Willebrand Factor Complex is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Antihemophilic Factor & von Willebrand Factor Complex include Takeda, Octapharma, Grifols and CSL Behring, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Antihemophilic Factor & von Willebrand Factor Complex, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antihemophilic Factor & von Willebrand Factor Complex, also provides the revenue of main regions and countries. Of the upcoming market potential for Antihemophilic Factor & von Willebrand Factor Complex, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antihemophilic Factor & von Willebrand Factor Complex revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antihemophilic Factor & von Willebrand Factor Complex market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Antihemophilic Factor & von Willebrand Factor Complex revenue, projected growth trends, production technology, application and end-user industry.

Antihemophilic Factor & von Willebrand Factor Complex Segment by Company

Takeda

Octapharma

Grifols

CSL Behring

Antihemophilic Factor & von Willebrand Factor Complex Segment by Type

10 ml

15 ml

5 ml

Antihemophilic Factor & von Willebrand Factor Complex Segment by Application

Hospital

Clinic

Antihemophilic Factor & von Willebrand Factor Complex Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihemophilic Factor & von Willebrand Factor Complex market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antihemophilic Factor & von Willebrand Factor Complex and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihemophilic Factor & von Willebrand Factor Complex.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Antihemophilic Factor & von Willebrand Factor Complex in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Antihemophilic Factor & von Willebrand Factor Complex company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antihemophilic Factor & von Willebrand Factor Complex revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 10 ml Major Player Table 3. 15 ml Major Player Table 4. 5 ml Major Player Table 5. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Clinic Major Player Table 8. Antihemophilic Factor & von Willebrand Factor Complex Industry Trends Table 9. Antihemophilic Factor & von Willebrand Factor Complex Industry Drivers Table 10. Antihemophilic Factor & von Willebrand Factor Complex Industry Opportunities and Challenges Table 11. Antihemophilic Factor & von Willebrand Factor Complex Industry Restraints Table 12. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Antihemophilic Factor & von Willebrand Factor Complex Market Share by Region (2021-2026) Table 15. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Antihemophilic Factor & von Willebrand Factor Complex Market Share by Region (2027-2032) Table 17. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share by Players (2021-2026) Table 19. Global Antihemophilic Factor & von Willebrand Factor Complex Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Antihemophilic Factor & von Willebrand Factor Complex Key Players Headquarters & Area Served Table 21. Global Antihemophilic Factor & von Willebrand Factor Complex Players, Product Type & Application Table 22. Global Antihemophilic Factor & von Willebrand Factor Complex Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Antihemophilic Factor & von Willebrand Factor Complex by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share by Type (2021-2026) Table 29. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share by Type (2027-2032) Table 30. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share by Application (2021-2026) Table 34. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share by Application (2027-2032) Table 35. Takeda Company Information Table 36. Takeda Business Overview Table 37. Takeda Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Takeda Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio Table 39. Takeda Recent Development Table 40. Octapharma Company Information Table 41. Octapharma Business Overview Table 42. Octapharma Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Octapharma Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio Table 44. Octapharma Recent Development Table 45. Grifols Company Information Table 46. Grifols Business Overview Table 47. Grifols Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Grifols Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio Table 49. Grifols Recent Development Table 50. CSL Behring Company Information Table 51. CSL Behring Business Overview Table 52. CSL Behring Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. CSL Behring Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio Table 54. CSL Behring Recent Development Table 55. North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2026) & (US$ Million) Table 56. North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2027-2032) & (US$ Million) Table 57. North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2026) & (US$ Million) Table 58. North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2027-2032) & (US$ Million) Table 59. North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 60. North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021-2026) & (US$ Million) Table 61. North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (US$ Million) & (2027-2032) Table 62. Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2026) & (US$ Million) Table 63. Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2027-2032) & (US$ Million) Table 64. Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2026) & (US$ Million) Table 65. Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2027-2032) & (US$ Million) Table 66. Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 67. Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021-2026) & (US$ Million) Table 68. Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (US$ Million) & (2027-2032) Table 69. China Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2026) & (US$ Million) Table 70. China Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2027-2032) & (US$ Million) Table 71. China Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2026) & (US$ Million) Table 72. China Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2027-2032) & (US$ Million) Table 73. Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2026) & (US$ Million) Table 74. Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2027-2032) & (US$ Million) Table 75. Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2026) & (US$ Million) Table 76. Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2027-2032) & (US$ Million) Table 77. Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 78. Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Region (US$ Million) & (2021-2026) Table 79. Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Region (US$ Million) & (2027-2032) Table 80. SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2026) & (US$ Million) Table 81. SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2027-2032) & (US$ Million) Table 82. SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2026) & (US$ Million) Table 83. SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2027-2032) & (US$ Million) Table 84. SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021-2026) & (US$ Million) Table 86. SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (US$ Million) & (2027-2032) Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Antihemophilic Factor & von Willebrand Factor Complex Image Figure 2. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size Share 2021 VS 2025 VS 2032 Figure 4. 10 ml Image Figure 5. 15 ml Image Figure 6. 5 ml Image Figure 7. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Clinic Image Figure 11. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size (US$ Million) & (2021-2032) Figure 12. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Antihemophilic Factor & von Willebrand Factor Complex Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Antihemophilic Factor & von Willebrand Factor Complex Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share by Type (2021-2032) Figure 19. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share by Application (2021-2032) Figure 22. North America Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Type (2021-2032) Figure 24. North America Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Application (2021-2032) Figure 25. North America Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Country (2021-2032) Figure 26. United States Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Type (2021-2032) Figure 31. Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Application (2021-2032) Figure 32. Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Country (2021-2032) Figure 33. Germany Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Type (2021-2032) Figure 43. China Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Application (2021-2032) Figure 44. Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Type (2021-2032) Figure 46. Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Application (2021-2032) Figure 47. Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Region (2021-2032) Figure 48. Japan Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Type (2021-2032) Figure 56. SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Application (2021-2032) Figure 57. SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Country (2021-2032) Figure 58. Brazil Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Antihemophilic Factor & von Willebrand Factor Complex Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • 10 ml
  • 15 ml
  • 5 ml
Applications
  • Hospital
  • Clinic
Companies covered
  • Takeda
  • Octapharma
  • Grifols
  • CSL Behring

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antihemophilic Factor & von Willebrand Factor Complex Market by Type
  3. 1.2.1 Global Antihemophilic Factor & von Willebrand Factor Complex Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 10 ml
  5. 1.2.3 15 ml
  6. 1.2.4 5 ml
  7. 1.3 Antihemophilic Factor & von Willebrand Factor Complex Market by Application
  8. 1.3.1 Global Antihemophilic Factor & von Willebrand Factor Complex Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Clinic
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Antihemophilic Factor & von Willebrand Factor Complex Market Dynamics
  1. 2.1 Antihemophilic Factor & von Willebrand Factor Complex Industry Trends
  2. 2.2 Antihemophilic Factor & von Willebrand Factor Complex Industry Drivers
  3. 2.3 Antihemophilic Factor & von Willebrand Factor Complex Industry Opportunities and Challenges
  4. 2.4 Antihemophilic Factor & von Willebrand Factor Complex Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Antihemophilic Factor & von Willebrand Factor Complex Market Perspective (2021-2032)
  2. 3.2 Global Antihemophilic Factor & von Willebrand Factor Complex Growth Trends by Region
  3. 3.2.1 Global Antihemophilic Factor & von Willebrand Factor Complex Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antihemophilic Factor & von Willebrand Factor Complex Market Size by Region (2021-2026)
  5. 3.2.3 Global Antihemophilic Factor & von Willebrand Factor Complex Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Players
  2. 4.1.1 Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Players (2021-2026)
  3. 4.1.2 Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Antihemophilic Factor & von Willebrand Factor Complex Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antihemophilic Factor & von Willebrand Factor Complex Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Antihemophilic Factor & von Willebrand Factor Complex Key Players Headquarters & Area Served
  7. 4.4 Global Antihemophilic Factor & von Willebrand Factor Complex Players, Product Type & Application
  8. 4.5 Global Antihemophilic Factor & von Willebrand Factor Complex Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Antihemophilic Factor & von Willebrand Factor Complex Market CR5 and HHI
  11. 4.6.3 2025 Antihemophilic Factor & von Willebrand Factor Complex Tier 1, Tier 2, and Tier 3
5 Antihemophilic Factor & von Willebrand Factor Complex Market Size by Type
  1. 5.1 Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2032)
  3. 5.3 Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share by Type (2021-2032)
6 Antihemophilic Factor & von Willebrand Factor Complex Market Size by Application
  1. 6.1 Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2032)
  3. 6.3 Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Octapharma
  8. 7.2.1 Octapharma Company Information
  9. 7.2.2 Octapharma Business Overview
  10. 7.2.3 Octapharma Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Octapharma Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio
  12. 7.2.5 Octapharma Recent Developments
  13. 7.3 Grifols
  14. 7.3.1 Grifols Company Information
  15. 7.3.2 Grifols Business Overview
  16. 7.3.3 Grifols Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Grifols Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio
  18. 7.3.5 Grifols Recent Developments
  19. 7.4 CSL Behring
  20. 7.4.1 CSL Behring Company Information
  21. 7.4.2 CSL Behring Business Overview
  22. 7.4.3 CSL Behring Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (2021-2026)
  23. 7.4.4 CSL Behring Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio
  24. 7.4.5 CSL Behring Recent Developments
8 North America
  1. 8.1 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue (2021-2032)
  2. 8.2 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2032)
  3. 8.2.1 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2026)
  4. 8.2.2 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2027-2032)
  5. 8.3 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Type (2021-2032)
  6. 8.4 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2032)
  7. 8.4.1 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2026)
  8. 8.4.2 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2027-2032)
  9. 8.5 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Application (2021-2032)
  10. 8.6 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country
  11. 8.6.1 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021-2026)
  13. 8.6.3 North America Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue (2021-2032)
  2. 9.2 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2032)
  3. 9.2.1 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2026)
  4. 9.2.2 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2027-2032)
  5. 9.3 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Type (2021-2032)
  6. 9.4 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2032)
  7. 9.4.1 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2026)
  8. 9.4.2 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2027-2032)
  9. 9.5 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Application (2021-2032)
  10. 9.6 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country
  11. 9.6.1 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021-2026)
  13. 9.6.3 Europe Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Antihemophilic Factor & von Willebrand Factor Complex Revenue (2021-2032)
  2. 10.2 China Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2032)
  3. 10.2.1 China Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2026)
  4. 10.2.2 China Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2027-2032)
  5. 10.3 China Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Type (2021-2032)
  6. 10.4 China Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2032)
  7. 10.4.1 China Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2026)
  8. 10.4.2 China Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2027-2032)
  9. 10.5 China Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue (2021-2032)
  2. 11.2 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2032)
  3. 11.2.1 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2026)
  4. 11.2.2 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2027-2032)
  5. 11.3 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Type (2021-2032)
  6. 11.4 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2032)
  7. 11.4.1 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2026)
  8. 11.4.2 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2027-2032)
  9. 11.5 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Application (2021-2032)
  10. 11.6 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country
  11. 11.6.1 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021-2026)
  13. 11.6.3 Asia Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue (2021-2032)
  2. 12.2 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Type (2027-2032)
  5. 12.3 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Application (2027-2032)
  9. 12.5 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country
  11. 12.6.1 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Antihemophilic Factor & von Willebrand Factor Complex Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst